Durvalumab
D910FC00001
Approved small_molecule completed
Quick answer
Durvalumab for Solid Tumor is a Approved program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Solid Tumor
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed